4Suppliers
5Customers
3Debt Items
9Related Chains

MannKind Corporation Suppliers

TickerNameConfidenceEvidence
UNITED-THERAPEUTICS UNITED-THERAPEUTICS 92% In 23 August 2021, the Company and UT entered into the CSA pursuant to which the Company is responsible for manufacturing and supplying to UT, and UT is responsible for purchasing from the Company
FDKP-SUPPLIER FDKP-SUPPLIER 90% In the past, we purchased FDKP, the primary component of Technosphere powders, from a major chemical manufacturer with facilities in Europe and North America.
V-GO-CONTRACT-MANUFACTURER V-GO-CONTRACT-MANUFACTURER 85% V-Go is manufactured for us by a contract manufacturer ("CMO") in Southern China using MannKind-owned, custom-designed, semi-automated manufacturing equipment and production lines.
PULM Pulmatrix, Inc. 72% Reciprocal relationship from PULM graph: Reciprocal relationship from MNKD graph: Reciprocal relationship from PULM graph: elopment services for the Product and $ million for the irrevocable license …

MannKind Corporation Customers

TickerNameConfidenceEvidence
UNITED-THERAPEUTICS UNITED-THERAPEUTICS 92% Total revenue from UT was as follows (in thousands): Three Months Ended March 31, 2026 2025 Revenue from UT Royalties (1) $ 32,749 $ 30,005 UT CSA 22,015 28,818 UT License Agreement 1,000 — Total rev…
PULM Pulmatrix, Inc. 72% Reciprocal relationship from PULM graph: primarily of costs incurred for the research and development of our preclinical and clinical candidates, and include: ● employee-related expenses, including s…
MANN-GROUP MANN-GROUP 62% revenue balance was $ 1.4 million, of which $ 0.2 million is classified as current and $ 1.2 million is classified as long term in the consolidated balance sheets. Amphastar — During the quarter ende…
N-A-MANN-GROUP N-A-MANN-GROUP 62% mary of Significant Accounting Policies . 89 Other Intangible Assets — Other intangible assets consisted of the following (in thousands): Estimated December 31, 2024 December 31, 2023 Useful Life (Ye…
ZEALAND-PHARMA-US-INC ZEALAND-PHARMA-US-INC 62% able, net $ 11,804 $ 14,901 ___________________________ (1) Includes the $ 1.1 million regulatory milestone payment receivable from Cipla. See Note 11 – Collaborations, Licensing and Other Arrangemen…

MannKind Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
MNKD-DEBT Debt stack $434.2M 90% Market cache reports total debt of $434.2M.
MNKD-DEBT-11031 Warrants outstanding: 21562500 90% xbrl warrant detail from xbrl 2020-12-31.
MNKD-DEBT-11032 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.

MannKind Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for MannKind Corporation.

MannKind Corporation Ownership

HolderNameConfidenceEvidence
MNKD-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 255 tracked holders.

MannKind Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
HALO Halozyme Therapeutics, Inc. 100.00 2
PULM Pulmatrix, Inc. 100.00 1 ['customer', 'supplier']
ORANY ORANGE 50.00 2
EOS Eaton Vance Enhanced Equity Income Fund II 50.00 2
LLY Eli Lilly and Company 50.00 2
AMPH Amphastar Pharmaceuticals, Inc. 38.88 1 ['receiving']
HANXIN HANXIN 24.13 2
MCK McKesson Corporation 23.09 2
CAH Cardinal Health, Inc. 23.09 2